Insight Molecular Diagnostics Shifts to Decentralized Transplant Monitoring Model and Plans Commercial Launch in 2027
IMDX Insight Molecular Diagnostics Inc
$1.77 -4.84%
View chart & analysis → - 1Insight Molecular Diagnostics reported a transition to a commercial execution model focusing on the decentralization of transplant monitoring.
- 2The FDA completed the substantive review phase 1 for GraftAssureDx in late July and requested additional information.
- 3Insight Molecular Diagnostics has begun patient enrollment to exceed its 80% positive predictive value target for GALACTIC registration.
So what's the key point?
Insight Molecular Diagnostics is changing how transplant status is checked and preparing to launch a product in 2027. Experts have requested more information regarding the product under review, and patient enrollment has also begun.
Source The Motley Fool +1 · View original ↗
Nothing hidden: past picks and how they did against the S&P 500.